Metformin hydrochloride

ADVERSE REACTIONS In a US double-blind clinical study of Metformin Hydrochloride Tablets in patients with type 2 diabetes, a total of 141patients received Metformin Hydrochloride Tablets therapy (up to 2550 mg per day) and 145 patients received placebo.Adverse reactions reported in greater than 5% of the Metformin Hydrochloride Tablets patients, and that were more common in Metformin Hydrochloride Tablets - than placebo-treated patients, are listed in Table 11. . Table 11: Most Common Adverse Reactions (>5.0 Percent) in Placebo-Controlled Studies of Metformin Hydrochloride Tablets Monotherapy Reactions that were more common in metformin Hydrochloride Extended-release Tablets - than placebo-treated patients. Metformin Hydrochloride Extended-release Tablets Monotherapy n=141) Placebo (n=145) Adverse Reaction % of Patients Diarrhea 53.2 11.7 Nausea/Vomiting 25.5 8.3 Flatulance 12.1 5.5 Asthenia 9.2 5.5 Indigestion 7.1 4.1 Abdominal Discomfort 6.4 4.8 Headache 5.7 4.8 Diarrhea led to discontinuation of study medication in 6% of patients treated with Metformin Hydrochloride Tablets. Additionally, the following adverse reactions were reported in ≥1.0% to ≤5.0% of Metformin Hydrochloride Tablets patients and were more commonly reported with Metformin Hydrochloride Tablets than placebo: abnormal stools, hypoglycemia, myalgia, lightheaded, dyspnea, nail disorder, rash, sweating increased, taste disorder,chest discomfort, chills, flu syndrome, flushing, palpitation. In worldwide clinical trials over 900 patients with type 2 diabetes have been treated with Metformin Hydrochloride Extended-release Tablets in placebo- and active-controlled studies. In placebo-controlled trials, 781 patients were administered Metformin Hydrochloride Extended-release Tablets and 195 patients received placebo. Adverse reactions reported in greater than 5% of the Metformin Hydrochloride Extended-release Tablets patients, and that were more common in Metformin Hydrochloride Extended-release Tablets - than placebo-treated patients, are listed in Table 12. Table 12: Most Common Adverse Reactions (>5.0 Percent) in Placebo-Controlled Studies of Metformin Hydrochloride Extended-release Tablets Reactions that were more common in metformin Hydrochloride Extended-release Tablets - than placebo-treated patients. Metformin Hydrochloride Extended-release Tablets n=781) Placebo (n=195) Adverse Reaction % of Patients Diarrhea 9.6 2.6 Nausea/Vomiting 6.5 1.5 Diarrhea led to discontinuation of study medication in 0.6% of patients treated with Metformin Hydrochloride Extended-release Tablets. Additionally, the following adverse reactions were reported in ≥1.0% to ≤5.0% of Metformin Hydrochloride Extended-release Tablets patients and were more commonly reported with Metformin Hydrochloride Extended-release Tablets than placebo: abdominal pain, constipation, distention abdomen, dyspepsia/heartburn, flatulence, dizziness, headache, upper respiratory infection, taste disturbance. Liver function test abnormalities or hepatitis, resolving upon metformin discontinuation, have been reported very rarely.

CONTRAINDICATIONS Metformin Hydrochloride is contraindicated in patients with: Renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥1.5 mg/dL [males], ≥1.4 mg/dL [females] or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see WARNINGS and PRECAUTIONS ). Known hypersensitivity to Metformin Hydrochloride. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Diabetic ketoacidosis should be treated with insulin. Metformin Hydrochloride should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function. (See also PRECAUTIONS. )

DESCRIPTION Metformin Hydrochloride Extended-release Tablets USP are oral antihyperglycemic drugs used in the management of type 2 diabetes. Metformin Hydrochloride (N,N-dimethylimidodicarbonimidic diamide Hydrochloride) is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. The structural formula is as shown: Metformin Hydrochloride is a white to off-white crystalline compound with a molecular formula of C 4 H 11 N 5 • HCl and a molecular weight of 165.63. Metformin Hydrochloride is freely soluble in water and is practically insoluble in acetone, ether, and chloroform. The pK a of metformin is 12.4. The pH of a 1% aqueous solution of metformin Hydrochloride is 6.68. Metformin Hydrochloride Extended-release Tablets USP contain 500 mg or 750 mg of Metformin Hydrochloride USP as the active ingredient. Metformin Hydrochloride Extended-release Tablets USP 500 mg and 750 mg contain the inactive ingredients microcrystalline cellulose, hypromellose, povidone, sodium carboxymethyl cellulose, and magnesium stearate. System Components and Performance- Metformin Hydrochloride Extended-release Tablets USP comprises a duel hydrophilic polymer matrix system. Metformin hydrochloride is combined with a drug release controlling polymers to form a monophasic matrix system. After administration, fluid from the gastrointestinal (GI) tract enters the tablet, causing the polymers to hydrate and swell. Drug is released slowly from the dosage form by a process of diffusion through the gel matrix that is essentially independent of pH. The hydrated polymer system is not rigid and is expected to be broken up by normal peristalsis in the GI tract. The biologically inert components of the tablet may occasionally remain intact during GI transit and will be eliminated in the feces as a soft, hydrated mass. The USP Dissolution Test is pending. structure

DOSAGE AND ADMINISTRATION There is no fixed dosage regimen for the management of hyperglycemia in patients with type 2 diabetes with Metformin Hydrochloride Extended-release Tablets or any other pharmacologic agent. Dosage of Metformin Hydrochloride Extended-release Tablets must be individualized on the basis of both effectiveness and tolerance, while not exceeding the maximum recommended daily doses. The maximum recommended daily dose of Metformin Hydrochloride Extended-release Tablets in adults is 2000 mg. Metformin Hydrochloride Extended-release Tablets should generally be given once daily with the evening meal. Metformin Hydrochloride Extended-release Tablets should be started at a low dose, with gradual dose escalation, both to reduce gastrointestinal side effects and to permit identification of the minimum dose required for adequate glycemic control of the patient. During treatment initiation and dose titration (see Recommended Dosing Schedule ), fasting plasma glucose should be used to determine the therapeutic response to Metformin Hydrochloride Extended-release Tablets and identify the minimum effective dose for the patient. Thereafter, glycosylated hemoglobin should be measured at intervals of approximately 3 months. The therapeutic goal should be to decrease both fasting plasma glucose and glycosylated hemoglobin levels to normal or near normal by using the lowest effective dose of Metformin Hydrochloride Extended-release Tablets either when used as monotherapy or in combination with sulfonylurea or insulin. Monitoring of blood glucose and glycosylated hemoglobin will also permit detection of primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication, and secondary failure, i.e., loss of an adequate blood glucose lowering response after an initial period of effectiveness. Short-term administration of Metformin Hydrochloride Extended-release Tablets may be sufficient during periods of transient loss of control in patients usually well-controlled on diet alone. Metformin Hydrochloride Extended-release Tablets must be swallowed whole and never crushed or chewed. Occasionally, the inactive ingredients of Metformin Hydrochloride Extended-release Tablets will be eliminated in the feces as a soft, hydrated mass. (See Patient Information printed below.)

OVERDOSAGE Overdose of metformin hydrochloride has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin Hydrochloride has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases (see WARNINGS ). Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdosage is suspected.

Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets) Glyburide - In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. Decreases in glyburide AUC and C max were observed, but were highly variable. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients ). Furosemide - A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration. Furosemide increased the metformin plasma and blood C max by 22% and blood AUC by 15%, without any significant change in metformin renal clearance. When administered with metformin, the C max and AUC of furosemide were 31% and 12% smaller, respectively, than when administered alone, and the terminal half-life was decreased by 32%, without any significant change in furosemide renal clearance. No information is available about the interaction of metformin and furosemide when coadministered chronically. Nifedipine - A single-dose, metformin-nifedipine drug interaction study in normal healthy volunteers demonstrated that coadministration of nifedipine increased plasma metformin C max and AUC by 20% and 9%, respectively, and increased the amount excreted in the urine. T max and half-life were unaffected. Nifedipine appears to enhance the absorption of metformin. Metformin had minimal effects on nifedipine. Cationic drugs - Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. Such interaction between metformin and oral cimetidine has been observed in normal healthy volunteers in both single- and multiple-dose, metformin-cimetidine drug interaction studies, with a 60% increase in peak metformin plasma and whole blood concentrations and a 40% increase in plasma and whole blood metformin AUC. There was no change in elimination half-life in the single-dose study. Metformin had no effect on cimetidine pharmacokinetics. Although such interactions remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of metformin hydrochloride and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system. Other - Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving metformin hydrochloride, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving metformin hydrochloride, the patient should be observed closely for hypoglycemia. In healthy volunteers, the pharmacokinetics of metformin and propranolol, and metformin and ibuprofen were not affected when coadministered in single-dose interaction studies. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid, as compared to the sulfonylureas, which are extensively bound to serum proteins.

CLINICAL PHARMACOLOGY Mechanism of Action Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms of action are different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects (except in special circumstances, see PRECAUTIONS ) and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.

Mechanism of Action Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms of action are different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects (except in special circumstances, see PRECAUTIONS ) and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.

Pharmacokinetics Absorption and Bioavailability The absolute bioavailability of a Metformin Hydrochloride 500 mg tablet given under fasting conditions is approximately 50% to 60%. Studies using single oral doses of Metformin Hydrochloride 500 to 1500 mg, and 850 to 2550 mg, indicate that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination. Food decreases the extent of and slightly delays the absorption of metformin, as shown by approximately a 40% lower mean peak plasma concentration (C max ), a 25% lower area under the plasma concentration versus time curve (AUC), and a 35-minute prolongation of time to peak plasma concentration (T max ) following administration of a single 850 mg tablet of metformin with food, compared to the same tablet strength administered fasting. The clinical relevance of these decreases is unknown. Following a single oral dose of Metformin Hydrochloride Extended-release tablet, C max is achieved with a median value of 7 hours and a range of 4 to 8 hours. Peak plasma levels are approximately 20% lower compared to the same dose of Metformin Hydrochloride tablet, however, the extent of absorption (as measured by AUC) is similar to Metformin Hydrochloride tablet. At steady state, the AUC and C max are less than dose proportional for Metformin Hydrochloride Extended-release Tablets within the range of 500 to 2000 mg administered once daily. Peak plasma levels are approximately 0.6, 1.1, 1.4, and 1.8 mcg/mL for 500, 1000, 1500, and 2000 mg once-daily doses, respectively. The extent of metformin absorption (as measured by AUC) from Metformin Hydrochloride Extended-release tablet at a 2000 mg once-daily dose is similar to the same total daily dose administered as Metformin Hydrochloride Tablets 1000 mg twice daily. After repeated administration of Metformin Hydrochloride Extended-release Tablets, metformin did not accumulate in plasma. Within-subject variability in C max and AUC of metformin from Metformin Hydrochloride Extended-release Tablets is comparable to that with Metformin Hydrochloride Tablets. Although the extent of metformin absorption (as measured by AUC) from the Metformin Hydrochloride Extended-release Tablets increased by approximately 50% when given with food, there was no effect of food on C max and T max of metformin. Both high and low fat meals had the same effect on the pharmacokinetics of Metformin Hydrochloride Extended-release Tablets.

20220222

3

Metformin hydrochloride Metformin hydrochloride CELLULOSE, MICROCRYSTALLINE HYPROMELLOSES POVIDONE K30 CARBOXYMETHYLCELLULOSE SODIUM MAGNESIUM STEARATE METFORMIN HYDROCHLORIDE METFORMIN white to off-white B115

Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and 1500 mg/kg/day, respectively. These doses are both approximately four times the maximum recommended human daily dose of 2000 mg based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female mice. Similarly, there was no tumorigenic potential observed with metformin in male rats. There was, however, an increased incidence of benign stromal uterine polyps in female rats treated with 900 mg/kg/day. There was no evidence of a mutagenic potential of metformin in the following in vitro tests: Ames test ( S. typhimurium ), gene mutation test (mouse lymphoma cells), or chromosomal aberrations test (human lymphocytes). Results in the in vivo mouse micronucleus test were also negative. Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately three times the maximum recommended human daily dose based on body surface area comparisons.

ANDA207427

Metformin hydrochloride

Metformin hydrochloride

71610-554

HUMAN PRESCRIPTION DRUG

ORAL

Laboratory Tests Response to all diabetic therapies should be monitored by periodic measurements of fasting blood glucose and glycosylated hemoglobin levels, with a goal of decreasing these levels toward the normal range. During initial dose titration, fasting glucose can be used to determine the therapeutic response. Thereafter, both glucose and glycosylated hemoglobin should be monitored. Measurements of glycosylated hemoglobin may be especially useful for evaluating long-term control (see also DOSAGE AND ADMINISTRATION ). Initial and periodic monitoring of hematologic parameters (e.g., hemoglobin/hematocrit and red blood cell indices) and renal function (serum creatinine) should be performed, at least on an annual basis. While megaloblastic anemia has rarely been seen with metformin hydrochloride tablet therapy, if this is suspected, vitamin B 12 deficiency should be excluded.

PRINCIPAL DISPLAY PANEL - 500 mg NDC 71610-554 - Metformin HCl ER, USP 500mg Tablets - Rx Only Bottle Label 500 mg

Distribution The apparent volume of distribution (V/F) of metformin following single oral doses of Metformin Hydrochloride 850 mg averaged 654 ± 358 L. Metformin is negligibly bound to plasma proteins, in contrast to sulfonylureas, which are more than 90% protein bound. Metformin partitions into erythrocytes, most likely as a function of time. At usual clinical doses and dosing schedules of Metformin Hydrochloride Tablets, steady state plasma concentrations of metformin are reached within 24 to 48 hours and are generally <1mcg/mL. During controlled clinical trials of Metformin Hydrochloride Tablets, maximum metformin plasma levels did not exceed 5 mcg/mL, even at maximum doses.

Information for Patients Patients should be informed of the potential risks and benefits of metformin hydrochloride and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose, glycosylated hemoglobin, renal function, and hematologic parameters. The risks of lactic acidosis, its symptoms, and conditions that predispose to its development, as noted in the WARNINGS and PRECAUTIONS sections, should be explained to patients. Patients should be advised to discontinue metformin hydrochloride immediately and to promptly notify their health practitioner if unexplained hyperventilation, myalgia, malaise, unusual somnolence, or other nonspecific symptoms occur. Once a patient is stabilized on any dose level of metformin hydrochloride, gastrointestinal symptoms, which are common during initiation of metformin therapy, are unlikely to be drug related. Later occurrence of gastrointestinal symptoms could be due to lactic acidosis or other serious disease. Patients should be counselled against excessive alcohol intake, either acute or chronic, while receiving metformin hydrochloride. Metformin hydrochloride alone does not usually cause hypoglycemia, although it may occur when metformin hydrochloride are used in conjunction with oral sulfonylureas and insulin. When initiating combination therapy, the risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. (See Patient Information printed below.) Patients should be informed that metformin Hydrochloride Extended-release Tablets must be swallowed whole and not crushed or chewed, and that the inactive ingredients may occasionally be eliminated in the feces as a soft mass that may resemble the original tablet.

Clinical Studies Metformin Hydrochloride Tablets In a double-blind, placebo-controlled, multicenter US clinical trial involving obese patients with type 2 diabetes whose hyperglycemia was not adequately controlled with dietary management alone (baseline fasting plasma glucose [FPG] of approximately 240 mg/dL), treatment with Metformin Hydrochloride Tablets (up to 2550 mg/day) for 29 weeks resulted in significant mean net reductions in fasting and postprandial plasma glucose (PPG) and hemoglobin A1c (HbA1c) of 59 mg/dL, 83 mg/dL, and 1.8%, respectively, compared to the placebo group (see Table 2 ). Table 2. Metformin vs Placebo Summary of Mean Changes from Baseline All patients on diet therapy at Baseline in Fasting Plasma Glucose, HbA1c and Body Weight, at Final Visit (29-week study) Metformin Hydrochloride Tablets (n=141) Placebo (n=145) p–Value FPG (mg/dL) Baseline Change at FINAL VISIT 241.5 -53.0 237.7 6.3 NS Not statistically significant 0.001 Hemoglobin A 1c (%) Baseline Change at FINAL VISIT 8.4 -1.4 8.2 0.4 NS 0.001 Body Weight (lbs) Baseline Change at FINAL VISIT 201.0 -1.4 206.0 -2.4 NS NS A 29-week, double-blind, placebo-controlled study of Metformin Hydrochloride Tablets and glyburide, alone and in combination, was conducted in obese patients with type 2 diabetes who had failed to achieve adequate glycemic control while on maximumdoses of glyburide (baseline FPG of approximately 250 mg/dL) (see Table 3). Patients randomized to the combination armstarted therapy with Metformin Hydrochloride Tablets 500 mgand glyburide 20 mg. At the end of each week of the first 4 weeks of the trial, these patients had theirdosages of Metformin Hydrochloride Tablets increased by 500 mg if they had failed to reach target fasting plasma glucose. After week 4, such dosage adjustments were made monthly, although no patient was allowed toexceed Metformin Hydrochloride Tablets 2500 mg. Patients in the Metformin Hydrochloride Tablets only arm(metformin plus placebo) followed the same titration schedule. At the end of the trial, approximately 70% of the patients in the combination group were taking Metformin Hydrochloride Tablets 2000 mg/glyburide 20 mg or Metformin Hydrochloride Tablets 2500 mg/glyburide 20 mg. Patients randomized to continue on glyburide experienced worsening of glycemiccontrol, with mean increases in FPG, PPG, and HbA1c of 14 mg/dL, 3 mg/dL, and 0.2%, respectively. Incontrast, those randomized to Metformin Hydrochloride Tablets (up to 2500 mg/day) experienced a slight improvement, with mean reductions in FPG, PPG, and HbA1c of 1 mg/dL, 6 mg/dL, and 0.4%, respectively. The combination of Metformin Hydrochloride Tablets and glyburide was effective in reducing FPG, PPG, and HbA1c levels by 63 mg/dL, 65 mg/dL, and 1.7%, respectively. Compared to results of glyburide treatment alone, the net differences with combination treatment were –77 mg/dL, –68 mg/dL, and –1.9%, respectively (see Table 3 ). Table 3. Combined Metformin Hydrochloride Tablets /Glyburide (Comb) vs Glyburide (Glyb) or Metformin Hydrochloride Tablets (Met) Monotherapy: Summary of Mean Changes from Baseline All patients on glyburide, 20 mg/day, at Baseline in Fasting Plasma Glucose, HbA 1c and Body Weight, at Final Visit (29-week study) p-values Comb (n=213) Glyb (n=209) MET (n=210) Glyb vs Comb MET vs Comb MET vs Glyb Fasting Plasma Glucose (mg/dL) Baseline Change at FINAL VISIT 250.5 -63.5 247.5 13.7 253.9 -0.9 NS Not statistically significant 0.001 NS 0.001 NS 0.025 Hemoglobin A 1c (%) Baseline Change at FINAL VISIT 8.8 -1.7 8.5 0.2 8.9 -0.4 NS 0.001 NS 0.001 0.007 0.001 Body Weight (lbs) Baseline Change at FINAL VISIT 202.2 0.9 203.0 -0.7 204.0 -8.4 NS 0.011 NS 0.001 NS 0.001 The magnitude of the decline in fasting blood glucose concentration following the institution of Metformin Hydrochloride Tablets therapy was proportional to the level of fasting hyperglycemia. Patients withtype 2 diabetes with higher fasting glucose concentrations experienced greater declines in plasma glucose and glycosylated hemoglobin. In clinical studies, Metformin Hydrochloride Tablets, alone or in combination with a sulfonylurea, lowered mean fastingserum triglycerides, total cholesterol, and LDL cholesterol levels, and had no adverse effects on otherlipid levels (see Table 4 ). Table 4. Summary of Mean Percent Change from Baseline of Major Serum Lipid Variables at Final Visit (29-week study) Metformin Hydrochloride Tablets vs Placebo Combined Metformin Hydrochloride Tablets/Glyburide vs Monotherapy Metformin Hydrochloride Tablets (n=141) Placebo (n=145) Metformin Hydrochloride Tablets (n=210) Metformin Hydrochloride Tablets / Glyburide (n=213) Glyburide (n=209) Total Cholesterol (mg/dL) Baseline 211.0 212.3 213.1 215.6 219.6 Mean % Change at FINAL VISIT -5% 1% -2% -4% 1% Total Triglycerides (mg/dL) Baseline 236.1 203.5 242.5 215.0 266.1 Mean % Change at FINAL VISIT -16% 1% -3% -8% 4% LDL-Cholesterol (mg/dL) Baseline 135.4 138.5 134.3 136.0 137.5 Mean % Change at FINAL VISIT -8% 1% -4% -6% 3% HDL-Cholesterol (mg/dL) Baseline 39.0 40.5 37.2 39.0 37.0 Mean % Change at FINAL VISIT 2% -1% 5% 3% 1% In contrast to sulfonylureas, body weight of individuals on Metformin Hydrochloride Tablets tended to remain stable oreven decrease somewhat (see Tables 2 and 3 ). A 24-week, double-blind, placebo-controlled study of Metformin Hydrochloride Tablets plus insulin versus insulin plusplacebo was conducted in patients with type 2 diabetes who failed to achieve adequate glycemic controlon insulin alone (see Table 5 ). Patients randomized to receive Metformin Hydrochloride Tablets plus insulin achieved a reduction in HbA 1c of 2.10%, compared to a 1.56% reduction in HbA 1c achieved by insulin plusplacebo. The improvement in glycemic control was achieved at the final study visit with 16% less insulin, 93.0 U/day vs 110.6 U/day, Metformin Hydrochloride Tablets plus insulin versus insulin plus placebo, respectively, p=0.04. Table 5. Combined Metformin Hydrochloride Tablets/Insulin vs Placebo/Insulin Summary of Mean Changes from Baseline in HbA 1c and Daily Insulin Dose Metformin Hydrochloride Tablets/ Insulin (n=26) Placebo/ Insulin (n=28) Treatment Difference Mean ± SE Hemoglobin A 1c (%) Baseline Change at FINAL VISIT 8.95 -2.10 9.32 -1.56 -0.54 ± 0.43 Statistically significant using analysis of covariance with baseline as covariate (p=0.04) Not significant using analysis of variance (values shown in table) Insulin Dose (U/day) Baseline Change at FINAL VISIT 93.12 -0.15 94.64 15.93 -16.08 ± 7.77 Statistically significant for insulin (p=0.04) A second double-blind, placebo-controlled study (n=51), with 16 weeks of randomized treatment, emonstrated that in patients with type 2 diabetes controlled on insulin for 8 weeks with an average HbA 1c of 7.46 ± 0.97%, the addition of Metformin Hydrochloride Tablets maintained similar glycemic control (HbA 1c 7.15 ± 0.61 vs 6.97 ± 0.62 for Metformin Hydrochloride Tablets plus insulin and placebo plus insulin, respectively) with 19% less insulin versus baseline (reduction of 23.68 ± 30.22 vs an increase of 0.43 ± 25.20 units for Metformin Hydrochloride Tablets plus insulin and placebo plus insulin, p<0.01). In addition, this study demonstrated that the combination of Metformin Hydrochloride Tablets plus insulin resulted in reduction in body weight of 3.11 ± 4.30 lbs,compared to an increase of 1.30 ± 6.08 lbs for placebo plus insulin, p=0.01. Metformin Hydrochloride Extended-release Tablets A 24-week, double-blind, placebo-controlled study of Metformin Hydrochloride Extended-release Tablets, taken once daily with the evening meal, was conducted in patients with type 2 diabetes who had failed to achieve glycemic control with diet and exercise (HbA ic 7.0%-10.0%, FPG 126-270 mg/dL). Patients entering the study had a mean baseline HbA ic of 8.0% and a mean baseline FPG of 176 mg/dL. After 12 weeks treatment, mean HbA1c had increased from baseline by 0.1% and mean FPG decreased from baseline by 2 mg/dL in the placebo group, compared with a decrease in mean HbA ic of 0.6% and a decrease in mean FPG of 23 mg/dL in patients treated with Metformin Hydrochloride Extended-release 1000 mg tablet once daily. Subsequently, the treatment dose was increased to 1500 mg once daily if HbA ic was ≥7.0% but <8.0% (patients with HbA ic ≥8.0% were discontinued from the study). At the final visit (24-week), mean HbA ic had increased 0.2% from baseline in placebo patients and decreased 0.6% with Metformin Hydrochloride Extended-release Tablets. A 16-week, double-blind, placebo-controlled, dose-response study of Metformin Hydrochloride Extended - Release Tablets, taken once daily with the evening meal or twice daily with meals, was conducted in patients with type 2 diabetes who had failed to achieve glycemic control with diet and exercise (HbA 1c 7.0%-11.0%, FPG 126-280 mg/dL). Changes in glycemic control and body weight are shown in Table 6 . Table 6: Summary of Mean Changes from Baseline All patients on diet therapy at Baseline in HbA 1c , Fasting Plasma Glucose, and Body Weight at Final Visit (16-week study) Metformin Hydrochloride Extended-release Tablets 500 mg Once Daily 1000 mg Once Daily 1500 mg Once Daily 2000 mg Once Daily 1000 mg Twice Daily Placebo Hemoglobin A 1 c (%) Baseline Change at FINAL VISIT p-value All comparisons versus Placebo ( n = 115 ) 8.2 -0.4 <0.001 ( n = 115 ) 8.4 -0.6 <0.001 ( n = 111 ) 8.3 -0.9 <0.001 ( n = 125 ) 8.4 -0.8 <0.001 ( n = 112 ) 8.4 -1.1 <0.001 ( n = 111 ) 8.4 0.1 - FPG ( mg / dL ) Baseline Change at FINAL VISIT p-value ( n = 126 ) 182.7 -15.2 <0.001 ( n = 118 ) 183.7 -19.3 <0.001 ( n = 120 ) 178.9 -28.5 <0.001 ( n = 132 ) 181.0 -29.9 <0.001 ( n = 122 ) 181.6 -33.6 <0.001 ( n = 113 ) 179.6 7.6 - Body Weight ( lbs ) Baseline Change at FINAL VISIT p-value ( n = 125 ) 192.9 -1.3 NS Not statistically significant ( n = 119 ) 191.8 -1.3 NS ( n = 117 ) 188.3 -0.7 NS ( n = 131 ) 195.4 -1.5 NS ( n = 119 ) 192.5 -2.2 NS ( n = 113 ) 194.3 -1.8 - Compared with placebo, improvement in glycemic control was seen at all dose levels of Metformin Hydrochloride Extended-release Tablets and treatment was not associated with any significant change in weight (see DOSAGE AND ADMINISTRATION for dosing recommendations for Metformin Hydrochloride Extended-release Tablets). A 24-week, double-blind, randomized study of Metformin Hydrochloride Extended-release Tablets, taken once daily with the evening meal, and Metformin Hydrochloride Tablets, taken twice daily (with breakfast and evening meal), was conducted in patients with type 2 diabetes who had been treated with Metformin Hydrochloride 500 mg tablet twice daily for at least 8 weeks prior to study entry. The Metformin Hydrochloride dose had not necessarily been titrated to achieve a specific level of glycemic control prior to study entry. Patients qualified for the study if HbA 1c was ≤8.5% and FPG was ≤200 mg/dL. Changes in glycemic control and body weight are shown in Table 7. Table 7: Summary of Mean Changes from Baseline All patients on Metformin Hydrochloride tablets 500 mg twice daily at Baseline in HbA 1c , Fasting Plasma Glucose, and Body Weight at Week 12 and at Final Visit (24-week study) Metformin Hydrochloride Metformin Hydrochloride Extended-release Tablets 500 mg Twice Daily 1000 mg Once Daily 1500 mg Once Daily Hemoglobin A 1 c (%) Baseline Change at 12 Weeks (95% CI) Change at FINAL VISIT (95% CI) ( n = 67 ) 7.06 0.14 (-0.03, 0.31) 0.14 n=68 (-0.04, 0.31) ( n = 72 ) 6.99 0.23 (0.10, 0.36) 0.27 (0.11, 0.43) ( n = 66 ) 7.02 0.04 (-0.08, 0.15) 0.13 (-0.02, 0.28) FPG ( mg / dL ) Baseline Change at 12 Weeks (95% CI) Change at FINAL VISIT (95% CI) ( n = 69 ) 127.2 12.9 (6.5, 19.4) 14.0 (7.0, 21.0) ( n = 72 ) 131.0 9.5 (4.4, 14.6) 11.5 (4.4, 18.6) ( n = 70 ) 131.4 3.7 (-0.4, 7.8) 7.6 (1.0, 14.2) Body Weight ( lbs ) Baseline Change at 12 Weeks (95% CI) Change at FINAL VISIT (95% CI) ( n = 71 ) 210.3 0.4 (-0.4, 1.5) 0.9 (-0.4, 2.2) ( n = 74 ) 202.8 0.9 (0.0, 2.0) 1.1 (-0.2, 2.4) ( n = 71 ) 192.7 0.7 (-0.4, 1.8) 0.9 (-0.4, 2.0) After 12 weeks of treatment, there was an increase in mean HbA 1c in all groups; in the Metformin Hydrochloride Extended-release Tablets 1000 mg group, the increase from baseline of 0.23% was statistically significant (see DOSAGE AND ADMINISTRATION ). Changes in lipid parameters in the previously described placebo-controlled dose-response study of Metformin Hydrochloride Extended-release Tablets are shown in Table 8. Table 8: Summary of Mean Percent Changes from Baseline All patients on diet therapy at Baseline in Major Lipid Variables at Final Visit (16-week study) Metformin Hydrochloride Extended-release Tablets 500 mg Once Daily 1000 mg Once Daily 1500 mg Once Daily 2000 mg Once Daily 1000 mg Twice Daily Placebo Total Cholesterol ( mg / dL ) Baseline Mean % Change at FINAL VISIT ( n = 120 ) 210.3 1.0% ( n = 113 ) 218.1 1.7% ( n = 110 ) 214.6 0.7% ( n = 126 ) 204.4 -1.6% ( n = 117 ) 208.2 -2.6% ( n = 110 ) 208.6 2.6% Total Triglycerides ( mg / dL ) Baseline Mean % Change at FINAL VISIT ( n = 120 ) 220.2 14.5% ( n = 113 ) 211.9 9.4% ( n = 110 ) 198.0 15.1% ( n = 126 ) 194.2 14.9% ( n = 117 ) 179.0 9.4% ( n = 110 ) 211.7 10.9% LDL - Cholesterol ( mg / dL ) Baseline Mean % Change at FINAL VISIT ( n = 119 ) 131.0 -1.4% ( n = 113 ) 134.9 -1.6% ( n = 109 ) 135.8 -3.5% ( n = 126 ) 125.8 -3.3% ( n = 117 ) 131.4 -5.5% ( n = 107 ) 131.9 3.2% HDL - Cholesterol ( mg / dL ) Baseline Mean % Change at FINAL VISIT ( n = 120 ) 40.8 6.2% ( n = 108 ) 41.6 8.6% ( n = 108 ) 40.6 5.5% ( n = 125 ) 40.2 6.1% ( n = 117 ) 42.4 7.1% ( n = 108 ) 39.4 5.8% Changes in lipid parameters in the previously described study of Metformin Hydrochloride Tablets and Metformin Hydrochloride Extended-release Tablets are shown in Table 9. Table 9: Summary of Mean Percent Changes from Baseline All patients on Metformin Hydrochloride Tablets 500 mg twice daily at Baseline in Major Lipid Variables at Final Visit (24-week study) Metformin Hydrochloride Tablets Metformin Hydrochloride Extended-release Tablets 500 mg Twice Daily 1000 mg Once Daily 1500 mg Once Daily Total Cholesterol ( mg / dL ) Baseline Mean % Change at FINAL VISIT ( n = 68 ) 199.0 0.1% ( n = 70 ) 201.9 1.3% ( n = 66 ) 201.6 0.1% Total Triglycerides ( mg / dL ) Baseline Mean % Change at FINAL VISIT ( n = 68 ) 178.0 6.3% ( n = 70 ) 169.2 25.3% ( n = 66 ) 206.8 33.4% LDL - Cholesterol ( mg / dL ) Baseline Mean %Change at FINAL VISIT ( n = 68 ) 122.1 -1.3% ( n = 70 ) 126.2 -3.3% ( n = 66 ) 115.7 -3.7% HDL - Cholesterol ( mg / dL ) Baseline Mean % Change at FINAL VISIT ( n = 68 ) 41.9 4.8% ( n = 70 ) 41.7 1.0% ( n = 65 ) 44.6 -2.1%

Geriatric Use Controlled clinical studies of metformin hydrochloride did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients, although other reported clinical experience has not identified differences in responses between the elderly and younger patients. Metformin is known to be substantially excreted by the kidney and because the risk of serious adverse reactions to the drug is greater in patients with impaired renal function, metformin hydrochloride should only be used in patients with normal renal function (see CONTRAINDICATIONS, WARNINGS , and CLINICAL PHARMACOLOGY: Pharmacokinetics ). Because aging is associated with reduced renal function, metformin Hydrochloride Extended-release Tablets should be used with caution as age increases. Care should be taken in dose selection and should be based on careful and regular monitoring of renal function. Generally, elderly patients should not be titrated to the maximum dose of metformin hydrochloride (see also WARNINGS and DOSAGE AND ADMINISTRATION ).

Nursing Mothers Studies in lactating rats show that metformin is excreted into milk and reaches levels comparable to those in plasma. Similar studies have not been conducted in nursing mothers. Because the potential for hypoglycemia in nursing infants may exist, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. If metformin hydrochloride are discontinued, and if diet alone is inadequate for controlling blood glucose, insulin therapy should be considered.

Pediatric Use The safety and effectiveness of Metformin Hydrochloride Tablets for the treatment of type 2 diabetes have been established in pediatric patients ages 10 to 16 years (studies have not been conducted in pediatric patients below the age of 10 years). Use of Metformin Hydrochloride Tablets in this age group is supported by evidence from adequate and well-controlled studies of Metformin Hydrochloride Tablets in adults with additional data from a controlled clinical study in pediatric patients ages 10 to 16 years with type 2 diabetes, which demonstrated a similar response in glycemic control to that seen in adults. (See CLINICAL PHARMACOLOGY: Pediatric Clinical Studies .) In this study, adverse effects were similar to those described in adults. (See ADVERSE REACTIONS: Pediatric Patients .) A maximum daily dose of 2000 mg is recommended. (See DOSAGE AND ADMINISTRATION: Recommended Dosing Schedule: Pediatrics .) Safety and effectiveness of Metformin Hydrochloride Extended - Release Tablets in pediatric patients have not been established.

Pregnancy Teratogenic Effects Recent information strongly suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities. Most experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible. Because animal reproduction studies are not always predictive of human response, metformin hydrochloride should not be used during pregnancy unless clearly needed. There are no adequate and well-controlled studies in pregnant women with metformin hydrochloride. Metformin was not teratogenic in rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about two and six times the maximum recommended human daily dose of 2000 mg based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin.

Teratogenic Effects Recent information strongly suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities. Most experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible. Because animal reproduction studies are not always predictive of human response, metformin hydrochloride should not be used during pregnancy unless clearly needed. There are no adequate and well-controlled studies in pregnant women with metformin hydrochloride. Metformin was not teratogenic in rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about two and six times the maximum recommended human daily dose of 2000 mg based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin.

HOW SUPPLIED Metformin Hydrochloride Extended-release TabletsUSP are available as follows: 500 mg Bottles of 90 NDC 72789-105-90 500 mg Bottles of 100 NDC 72789-105-01 500 mg Bottles of 180 NDC 72789-105-93 500 mg Bottles of 500 NDC 72789-105-82 500 mg Bottles of 1000 NDC 72789-105-95 750 mg Bottles of 90 NDC 72789-106-90 750 mg Bottles of 100 NDC 72789-106-01 750 mg Bottles of 180 NDC 72789-106-93 750 mg Bottles of 500 NDC 72789-106-82 750 mg Bottles of 1000 NDC 72789-106-95 Metformin Hydrochloride Extended-release Tablets USP, 500 mg are white to off-white color, round, biconvex tablet, having B115 on one side and plain on the other. Metformin Hydrochloride Extended-release Tablets USP, 750 mg are white to off-white color, capsule shape, biconvex tablet, having B116 on one side and plain on the other.

Storage Store at 20° - 25° C (68° - 77° F); excursions permitted to 15° - 30° C (59° - 86° F). [See USP Controlled Room Temperature.] Dispense in light-resistant containers.

WARNINGS Lactic Acidosis: Lactic acidosis is a rare, but serious, metabolic complication that can occur due to metformin accumulation during treatment with Metformin Hydrochloride; when it occurs, it is fatal in approximately 50% of cases. Lactic acidosis may also occur in association with a number of pathophysiologic conditions, including diabetes mellitus, and whenever there is significant tissue hypoperfusion and hypoxemia. Lactic acidosis is characterized by elevated blood lactate levels (>5 mmol/L), decreased blood pH, electrolyte disturbances with an increased anion gap, and an increased lactate/pyruvate ratio. When metformin is implicated as the cause of lactic acidosis, metformin plasma levels >5 μg/mL are generally found. The reported incidence of lactic acidosis in patients receiving metformin Hydrochloride is very low (approximately 0.03 cases/1000 patient-years, with approximately 0.015 fatal cases/1000 patientyears). In more than 20,000 patient-years exposure to metformin in clinical trials, there were no reports of lactic acidosis. Reported cases have occurred primarily in diabetic patients with significant renal insufficiency, including both intrinsic renal disease and renal hypoperfusion, often in the setting of multiple concomitant medical/surgical problems and multiple concomitant medications. Patients with congestive heart failure requiring pharmacologic management, in particular those with unstable or acute congestive heart failure who are at risk of hypoperfusion and hypoxemia, are at increased risk of lactic acidosis. The risk of lactic acidosis increases with the degree of renal dysfunction and the patient's age. The risk of lactic acidosis may, therefore, be significantly decreased by regular monitoring of renal function in patients taking Metformin Hydrochloride by use of the minimum effective dose of Metformin Hydrochloride. In particular, treatment of the elderly should be accompanied by careful monitoring of renal function. Metformin Hydrochloride treatment should not be initiated in patients ≥80 years of age unless measurement of creatinine clearance demonstrates that renal function is not reduced, as these patients are more susceptible to developing lactic acidosis. In addition, Metformin Hydrochloride should be promptly withheld in the presence of any condition associated with hypoxemia, dehydration, or sepsis. Because impaired hepatic function may significantly limit the ability to clear lactate, Metformin Hydrochloride should generally be avoided in patients with clinical or laboratory evidence of hepatic disease. Patients should be cautioned against excessive alcohol intake, either acute or chronic, when taking Metformin Hydrochloride, since alcohol potentiates the effects of metformin Hydrochloride on lactate metabolism. In addition, Metformin Hydrochloride should be temporarily discontinued prior to any intravascular radiocontrast study and for any surgical procedure (see also PRECAUTIONS ). The onset of lactic acidosis often is subtle, and accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and nonspecific abdominal distress. There may be associated hypothermia, hypotension, and resistant bradyarrhythmias with more marked acidosis. The patient and the patient's physician must be aware of the possible importance of such symptoms and the patient should be instructed to notify the physician immediately if they occur (see also PRECAUTIONS ). Metformin Hydrochloride should be withdrawn until the situation is clarified. Serum electrolytes, ketones, blood glucose, and if indicated, blood pH, lactate levels, and even blood metformin levels may be useful. Once a patient is stabilized on any dose level of Metformin Hydrochloride, gastrointestinal symptoms, which are common during initiation of therapy, are unlikely to be drug related. Later occurrence of gastrointestinal symptoms could be due to lactic acidosis or other serious disease. Levels of fasting venous plasma lactate above the upper limit of normal but less than 5 mmol/L in patients taking Metformin Hydrochloride do not necessarily indicate impending lactic acidosis and may be explainable by other mechanisms, such as poorly controlled diabetes or obesity, vigorous physical activity, or technical problems in sample handling. (See also PRECAUTIONS .) Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia). Lactic acidosis is a medical emergency that must be treated in a hospital setting. In a patient with lactic acidosis who is taking Metformin Hydrochloride, the drug should be discontinued immediately and general supportive measures promptly instituted. Because metformin Hydrochloride is dialyzable (with a clearance of up to 170 mL/min under good hemodynamic conditions), prompt hemodialysis is recommended to correct the acidosis and remove the accumulated metformin. Such management often results in prompt reversal of symptoms and recovery. (See also CONTRAINDICATIONS and PRECAUTIONS .)

General Macrovascular Outcomes - There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with metformin hydrochloride or any other antidiabetic drug. Monitoring of renal function - Metformin is known to be substantially excreted by the kidney, and the risk of metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. Thus, patients with serum creatinine levels above the upper limit of normal for their age should not receive metformin hydrochloride. In patients with advanced age, metformin hydrochloride should be carefully titrated to establish the minimum dose for adequate glycemic effect, because aging is associated with reduced renal function. In elderly patients, particularly those ≥80 years of age, renal function should be monitored regularly and, generally, metformin Hydrochloride Extended-release Tablets should not be titrated to the maximum dose (see WARNINGS and DOSAGE AND ADMINISTRATION ). Before initiation of metformin hydrochloride therapy and at least annually hereafter, renal function should be assessed and verified as normal. In patients in whom development of renal dysfunction is anticipated, renal function should be assessed more frequently and metformin hydrochloride discontinued if evidence of renal impairment is present. Use of concomitant medications that may affect renal function or metformin disposition - Concomitant medication(s) that may affect renal function or result in significant hemodynamic change or may interfere with the disposition of metformin, such as cationic drugs that are eliminated by renal tubular secretion (see PRECAUTIONS: Drug Interactions ), should be used with caution. Radiologic studies involving the use of intravascular iodinated contrast materials (for example, intravenous urogram, intravenous cholangiography, angiography, and computed tomography (CT) scans with intravascular contrast materials) - Intravascular contrast studies with iodinated materials can lead to acute alteration of renal function and have been associated with lactic acidosis in patients receiving metformin (see CONTRAINDICATIONS ). Therefore, in patients in whom any such study is planned, metformin hydrochloride should be temporarily discontinued at the time of or prior to the procedure, and withheld for 48 hours subsequent to the procedure and reinstituted only after renal function has been re-evaluated and found to be normal. Hypoxic states - Cardiovascular collapse (shock) from whatever cause, acute congestive heart failure, acute myocardial infarction and other conditions characterized by hypoxemia have been associated with lactic acidosis and may also cause prerenal azotemia. When such events occur in patients on metformin hydrochloride therapy, the drug should be promptly discontinued. Surgical procedures - Metformin hydrochloride therapy should be temporarily suspended for any surgical procedure (except minor procedures not associated with restricted intake of food and fluids) and should not be restarted until the patient's oral intake has resumed and renal function has been evaluated as normal. Alcohol intake - Alcohol is known to potentiate the effect of metformin on lactate metabolism. Patients, therefore, should be warned against excessive alcohol intake, acute or chronic, while receiving metformin hydrochloride. Impaired hepatic function - Since impaired hepatic function has been associated with some cases of lactic acidosis, metformin hydrochloride should generally be avoided in patients with clinical or laboratory evidence of hepatic disease. Vitamin B 12 levels - In controlled clinical trials of metformin Hydrochloride Tablets of 29 weeks duration, a decrease to subnormal levels of previously normal serum vitamin B 12 levels, without clinical manifestations, was observed in approximately 7% of patients. Such decrease, possibly due to interference with B 12 absorption from the B 12 -intrinsic factor complex, is, however, very rarely associated with anemia and appears to be rapidly reversible with discontinuation of metformin Hydrochloride Tablets or vitamin B 12 supplementation. Measurement of hematologic parameters on an annual basis is advised in patients on metformin hydrochloride and any apparent abnormalities should be appropriately investigated and managed (see PRECAUTIONS: Laboratory Tests ). Certain individuals (those with inadequate vitamin B 12 or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B 12 levels. In these patients, routine serum vitamin B 12 measurements at two- to three year intervals may be useful. Change in clinical status of patients with previously controlled type 2 diabetes - A patient with type 2 diabetes previously well controlled on metformin hydrochloride who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. Evaluation should include serum electrolytes and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate, and metformin levels. If acidosis of either form occurs, metformin hydrochloride must be stopped immediately and other appropriate corrective measures initiated (see also WARNINGS ). Hypoglycemia - Hypoglycemia does not occur in patients receiving metformin Hydrochloride Extended-release Tablets alone under usual circumstances of use, but could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with other glucose-lowering agents (such as sulfonylureas and insulin) or ethanol. Elderly, debilitated, or malnourished patients, and those with adrenal or pituitary insufficiency or alcohol intoxication are particularly susceptible to hypoglycemic effects. Hypoglycemia may be difficult to recognize in the elderly, and in people who are taking beta-adrenergic blocking drugs. Loss of control of blood glucose - When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a temporary loss of glycemic control may occur. At such times, it may be necessary to withhold metformin hydrochloride and temporarily administer insulin. Metformin hydrochloride may be reinstituted after the acute episode is resolved. The effectiveness of oral antidiabetic drugs in lowering blood glucose to a targeted level decreases in many patients over a period of time. This phenomenon, which may be due to progression of the underlying disease or to diminished responsiveness to the drug, is known as secondary failure, to distinguish it from primary failure in which the drug is ineffective during initial therapy. Should secondary failure occur with either metformin hydrochloride or sulfonylurea monotherapy, combined therapy with metformin hydrochloride and sulfonylurea may result in a response. Should secondary failure occur with combined metformin hydrochloride/sulfonylurea therapy, it may be necessary to consider therapeutic alternatives including initiation of insulin therapy.

PRECAUTIONS General Macrovascular Outcomes - There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with metformin hydrochloride or any other antidiabetic drug. Monitoring of renal function - Metformin is known to be substantially excreted by the kidney, and the risk of metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. Thus, patients with serum creatinine levels above the upper limit of normal for their age should not receive metformin hydrochloride. In patients with advanced age, metformin hydrochloride should be carefully titrated to establish the minimum dose for adequate glycemic effect, because aging is associated with reduced renal function. In elderly patients, particularly those ≥80 years of age, renal function should be monitored regularly and, generally, metformin Hydrochloride Extended-release Tablets should not be titrated to the maximum dose (see WARNINGS and DOSAGE AND ADMINISTRATION ). Before initiation of metformin hydrochloride therapy and at least annually hereafter, renal function should be assessed and verified as normal. In patients in whom development of renal dysfunction is anticipated, renal function should be assessed more frequently and metformin hydrochloride discontinued if evidence of renal impairment is present. Use of concomitant medications that may affect renal function or metformin disposition - Concomitant medication(s) that may affect renal function or result in significant hemodynamic change or may interfere with the disposition of metformin, such as cationic drugs that are eliminated by renal tubular secretion (see PRECAUTIONS: Drug Interactions ), should be used with caution. Radiologic studies involving the use of intravascular iodinated contrast materials (for example, intravenous urogram, intravenous cholangiography, angiography, and computed tomography (CT) scans with intravascular contrast materials) - Intravascular contrast studies with iodinated materials can lead to acute alteration of renal function and have been associated with lactic acidosis in patients receiving metformin (see CONTRAINDICATIONS ). Therefore, in patients in whom any such study is planned, metformin hydrochloride should be temporarily discontinued at the time of or prior to the procedure, and withheld for 48 hours subsequent to the procedure and reinstituted only after renal function has been re-evaluated and found to be normal. Hypoxic states - Cardiovascular collapse (shock) from whatever cause, acute congestive heart failure, acute myocardial infarction and other conditions characterized by hypoxemia have been associated with lactic acidosis and may also cause prerenal azotemia. When such events occur in patients on metformin hydrochloride therapy, the drug should be promptly discontinued. Surgical procedures - Metformin hydrochloride therapy should be temporarily suspended for any surgical procedure (except minor procedures not associated with restricted intake of food and fluids) and should not be restarted until the patient's oral intake has resumed and renal function has been evaluated as normal. Alcohol intake - Alcohol is known to potentiate the effect of metformin on lactate metabolism. Patients, therefore, should be warned against excessive alcohol intake, acute or chronic, while receiving metformin hydrochloride. Impaired hepatic function - Since impaired hepatic function has been associated with some cases of lactic acidosis, metformin hydrochloride should generally be avoided in patients with clinical or laboratory evidence of hepatic disease. Vitamin B 12 levels - In controlled clinical trials of metformin Hydrochloride Tablets of 29 weeks duration, a decrease to subnormal levels of previously normal serum vitamin B 12 levels, without clinical manifestations, was observed in approximately 7% of patients. Such decrease, possibly due to interference with B 12 absorption from the B 12 -intrinsic factor complex, is, however, very rarely associated with anemia and appears to be rapidly reversible with discontinuation of metformin Hydrochloride Tablets or vitamin B 12 supplementation. Measurement of hematologic parameters on an annual basis is advised in patients on metformin hydrochloride and any apparent abnormalities should be appropriately investigated and managed (see PRECAUTIONS: Laboratory Tests ). Certain individuals (those with inadequate vitamin B 12 or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B 12 levels. In these patients, routine serum vitamin B 12 measurements at two- to three year intervals may be useful. Change in clinical status of patients with previously controlled type 2 diabetes - A patient with type 2 diabetes previously well controlled on metformin hydrochloride who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. Evaluation should include serum electrolytes and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate, and metformin levels. If acidosis of either form occurs, metformin hydrochloride must be stopped immediately and other appropriate corrective measures initiated (see also WARNINGS ). Hypoglycemia - Hypoglycemia does not occur in patients receiving metformin Hydrochloride Extended-release Tablets alone under usual circumstances of use, but could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with other glucose-lowering agents (such as sulfonylureas and insulin) or ethanol. Elderly, debilitated, or malnourished patients, and those with adrenal or pituitary insufficiency or alcohol intoxication are particularly susceptible to hypoglycemic effects. Hypoglycemia may be difficult to recognize in the elderly, and in people who are taking beta-adrenergic blocking drugs. Loss of control of blood glucose - When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a temporary loss of glycemic control may occur. At such times, it may be necessary to withhold metformin hydrochloride and temporarily administer insulin. Metformin hydrochloride may be reinstituted after the acute episode is resolved. The effectiveness of oral antidiabetic drugs in lowering blood glucose to a targeted level decreases in many patients over a period of time. This phenomenon, which may be due to progression of the underlying disease or to diminished responsiveness to the drug, is known as secondary failure, to distinguish it from primary failure in which the drug is ineffective during initial therapy. Should secondary failure occur with either metformin hydrochloride or sulfonylurea monotherapy, combined therapy with metformin hydrochloride and sulfonylurea may result in a response. Should secondary failure occur with combined metformin hydrochloride/sulfonylurea therapy, it may be necessary to consider therapeutic alternatives including initiation of insulin therapy.